It was estimated that as of 2022 around 24.4 million people in the United States had been diagnosed with diabetes. The number of people diagnosed with diabetes in the U.S. has increased in recent years and the disease is now a major health issue. Diabetes is now the eighth leading cause of death in the United States, accounting for three percent of all deaths.

What is prediabetes? A person is considered to have prediabetes if their blood sugar levels are higher than normal but not high enough to be diagnosed with type 2 diabetes. As of 2021, it was estimated that around 53 million men and 44 million women in the United States had prediabetes. However, according to the CDC, around 80 percent of these people do not know they have this condition. Not only does prediabetes increase the risk of developing type 2 diabetes, but also increases the risk of heart disease and stroke. The states with the highest share of adults who had ever been told they have prediabetes are Hawaii, California, and Alaska.

The prevalence of diabetes in the United States As of 2022, around 8.4 percent of adults in the United States had been diagnosed with diabetes, an increase from six percent in the year 2000. Diabetes is much more common among older adults, with almost a quarter of those aged 65 years and older diagnosed with diabetes, compared to just three percent of those aged 18 to 44 years. The states with the highest prevalence of diabetes among adults are Alabama, Mississippi, and West Virginia, while Colorado and Alaska report the lowest rates. In Alabama, around 17 percent of adults have been diagnosed with diabetes.

This forecast represents the total number of people in the United States in 2025 with diabetes, sorted by characteristic. In 2025, some 53.1 million people are expected to have diabetes in the United States.

The dataset consists of 19 variables on 403 subjects from 1046 subjects who were interviewed in a study to understand the prevalence of obesity, diabetes, and other cardiovascular risk factors in central Virginia for African Americans.

This forecast represents the number of people in the United States in 2025 with diagnosed and undiagnosed diabetes, divided by characteristic. In 2025, some 38.7 million people are expected to be diagnosed with diabetes and some 14.4 million people are expected to live with undiagnosed diabetes.

In 2022, there were almost 1.53 million people who were newly diagnosed with diabetes in the United States. This statistic represents the number of new cases of diagnosed diabetes among U.S. adults per year from 2000 to 2022, in thousands of people.

The average for 2021 based on 20 countries was 8.73 percent. The highest value was in Mexico: 16.9 percent and the lowest value was in Ecuador: 4.4 percent. The indicator is available from 2000 to 2021. Below is a chart for all countries where data are available.

The North America Diabetes Care Devices Market report segments the industry into Product (Monitoring Devices, Management Devices) and Geography (United States, Canada, Rest of North America). Get five years of historical data alongside five-year market forecasts.

Context:

Diabetes is a widespread chronic disease affecting millions of Americans each year, imposing a substantial financial burden on the economy. It impairs the body's ability to regulate blood glucose levels, leading to a range of health issues such as heart disease, vision loss, limb amputation, and kidney disease. Diabetes occurs when the body either fails to produce sufficient insulin or cannot use the insulin produced effectively. Insulin is crucial for enabling cells to utilize sugars from the bloodstream for energy.

Though there is no cure for diabetes, lifestyle changes such as weight management, healthy eating, and regular physical activity, along with medical treatments, can help manage the disease. Early detection and intervention are vital, making predictive models for diabetes risk valuable tools for healthcare providers and public health officials.

As of 2018, the CDC reported that 34.2 million Americans have diabetes, with 88 million having prediabetes. Alarmingly, a significant portion of those affected are unaware of their condition. Type II diabetes, the most prevalent form, varies in prevalence based on age, education, income, location, race, and other social determinants of health. The economic impact is substantial, with diagnosed diabetes costing approximately $327 billion annually, and total costs, including undiagnosed cases and prediabetes, nearing $400 billion.

Content: The dataset originates from the Behavioral Risk Factor Surveillance System (BRFSS), an annual telephone survey by the CDC since 1984, collecting data on health-related risk behaviors, chronic health conditions, and preventative service usage. For this project, the 2015 BRFSS dataset available on Kaggle was used, featuring responses from 441,455 individuals across 330 features.

The dataset includes three files:

1. diabetes_012_health_indicators_BRFSS2015.csv: Contains 253,680 responses with 21 features. The target variable, Diabetes_012, has 3 classes: 0 (no diabetes or only during pregnancy), 1 (prediabetes), and 2 (diabetes). This dataset is imbalanced.

2. diabetes_binary_5050split_health_indicators_BRFSS2015.csv: Contains 70,692 responses with 21 features, balanced 50-50 between individuals with no diabetes and those with prediabetes or diabetes. The target variable, Diabetes_binary, has 2 classes: 0 (no diabetes) and 1 (prediabetes or diabetes).

3. diabetes_binary_health_indicators_BRFSS2015.csv: Contains 253,680 responses with 21 features, with the target variable Diabetes_binary having 2 classes: 0 (no diabetes) and 1 (prediabetes or diabetes). This dataset is not balanced.

Research Questions: - Can BRFSS survey questions accurately predict diabetes? - What risk factors are most indicative of diabetes risk? - Can a subset of risk factors effectively predict diabetes risk? - Can a shorter questionnaire be developed from the BRFSS using feature selection to predict diabetes risk?

Acknowledgements: This dataset was not created by me; it is a cleaned and consolidated version of the BRFSS 2015 dataset available on Kaggle. The original dataset and the data cleaning notebook can be found here.

Inspiration: This work was inspired by Zidian Xie et al.'s study on building risk prediction models for Type 2 diabetes using machine learning techniques on the 2014 BRFSS dataset. The study can be found here.

The North America Diabetes Drugs Market report segments the industry into Insulins (Basal or Long Acting Insulins, Bolus or Fast Acting Insulins, Traditional Human Insulins, Biosimilar Insulins), Oral Anti-Diabetic Drugs (Biguanides, Alpha-Glucosidase Inhibitors, and more), Non-Insulin Injectable Drugs (GLP-1 Receptor Agonists, Amylin Analogue), Combination Drugs (Insulin Combinations, Oral Combinations), and Geography.

Explore American Diabetes Association through data from visualizations to datasets, all based on diverse sources.

The Latin America Diabetes Care Devices Market report segments the industry into Monitoring Devices (Self-monitoring Blood Glucose Device, Continuous Glucose Monitoring Device), Management Devices (Insulin Pump, Insulin Syringes, Cartridges in Reusable Pens, Disposable Pens, Jet Injectors), and Geography (Brazil, Mexico, Rest of Latin America). Get five years of historical data alongside five-year market forecasts.

Financial overview and grant giving statistics of American Diabetes Association Research Foundation Inc

The Latin America Human Insulin Drugs Market is Segmented Into Product Type (Insulin Drugs, Oral Anti-Diabetes Drugs, And Non-Insulin Injectable Drugs) and Geography. The Report Offers the Value (in USD) and Volume (in Units) for the Above Segments.

North America Digital Diabetes Management Market Overview: The North America digital diabetes management market is projected to grow at a CAGR of 6.21% from 2025 to 2033, reaching a market size of Million in 2033. The growth is attributed to the increasing prevalence of diabetes, rising healthcare expenditure, technological advancements, and government initiatives. The rising demand for remote patient monitoring and personalized treatment plans drives the adoption of digital devices. Key Drivers and Trends: The key drivers of the market include the growing technological advancements in glucose monitoring, data analytics, and personalized therapy. Telemedicine services and remote patient monitoring systems improve patient care and management. Moreover, government initiatives and reimbursement policies supporting the adoption of digital diabetes management solutions further fuel market growth. However, challenges such as cybersecurity concerns, ethical considerations, and lack of reimbursement for certain services may restrain market growth. Market Size: USD 10.2 Billion in 2022, to grow to USD 17.2 Billion by 2029, at a CAGR of 7.2%. Recent developments include: April 2023: Abbott has announced the clearance of its FreeStyle Libre 3 integrated continuous glucose monitoring (iCGM) system by the U.S. Food and Drug Administration (FDA). This system includes a reader that has been approved as a standalone device. Notably, the glucose sensor used in this system is the smallest, thinnest, and most discreet in the world. Abbott is now focused on expediting the process of getting the FreeStyle Libre 3 system included in Medicare's list of covered systems., March 2022: Dexcom released G7 first in the U.K. and will expand the launch across Europe throughout 2022. Meanwhile, the CGM system currently is under review by the Food and Drug Administration for an eventual U.S. release.. Key drivers for this market are: Increasing Number of Preterm and Low-weight Births, Advanced Technology in Fetal and Prenatal Monitoring. Potential restraints include: Stringent Regulatory Procedures. Notable trends are: Monitoring Devices is Having the Highest Market Share in Current Year.

As of 2024, Mexico was the Latin American country with the highest number of adults with diabetes among selected countries in the region, reaching over ********** adults. That year, the adult population living with diabetes in Brazil amounted to more than ********** people, while Argentina reported around *********** adults with diabetes.

The North America Oral Anti-Diabetic Drug Market report segments the industry into By Drug Types (Biguanides, Alpha-Glucosidase Inhibitors, Dopamine D2 Receptor Agonist, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides), By Patient Type (Adults, Geriatric, Pediatric), and Geography (United States, Canada, Mexico). Get five years of historical data alongside five-year market forecasts.

Genomic data set on Type 2 Diabetes in African-Americans derived via admixture mapping, a method for genome-wide association analysis based on admixture-generated linkage disequilibrium. This collaborative group has identified 1,478 African Americans with Type 2 Diabetes (T2D) from the Jackson Heart Study and Multiethnic Cohort Study, as well as 498 controls from the Jackson Heart Study who are normoglycemic despite high body mass index and older age. All samples were genotyped (using the Illumina BeadLab platform) for 1,291 polymorphic markers chosen to be extremely different in frequency between west Africans and European Americans. Evidence for association to diabetes at each marker as reported by the ANCESTRYMAP software are reported in the downloadable table. They calculate that this study has statistical power to detect loci where African or European ancestry on average confers multiplicative increased risk of 1.35-fold or more. The fact that they did not detect a statistically significant signal of association in the scan suggests that any genetic risk factors for T2D do not confer different risks due to ancestry that differ by this factor. The genome scan results are publicly available (Excel file) prior to publication so that researchers interested in the genetics of T2D can use the results of the scan to prioritize follow-up of any regions of interest.

IntroductionIntensive lifestyle intervention remains an effective modality to reduce diabetes incidence and delay the progression to type 2 diabetes. The primary aim of this study was to pilot-test the feasibility and acceptability of a culturally and linguistically tailored web-based DPP intervention among Chinese Americans with prediabetes living in New York City.MethodsThirteen Chinese American participants with prediabetes were recruited to complete a 1-year web-based Diabetes Prevention Program (DPP) lifestyle intervention. Quantitative and qualitative measures such as retention rate and data collected from web-based questionnaires and focus groups were collected and analyzed to assess study feasibility and acceptability.Results and DiscussionParticipants were receptive to the program through high engagement, retention and satisfaction. Retention rate was 85%. 92% of participants completed at least 16 sessions out of 22 sessions. Post-trial surveys indicated high satisfaction of 27.2/32 based on Client Satisfaction Questionnaire (CSQ-8) score. Participants expressed the program increased their knowledge and methods to prevent onset of type 2 diabetes such as incorporating healthy eating habits and increasing physical activities. Although not a primary outcome, there was a significant weight reduction of 2.3% at the end of month 8 of the program (p 

The US diabetes devices market, a significant segment of the global market, is experiencing robust growth, driven by the rising prevalence of diabetes and an aging population. The market, valued at approximately $25.16 billion in 2025, is projected to expand at a Compound Annual Growth Rate (CAGR) of 6.27% from 2025 to 2033. This growth is fueled by several key factors: increasing adoption of continuous glucose monitoring (CGM) systems offering improved diabetes management, technological advancements leading to smaller, more user-friendly devices, and growing awareness of the benefits of proactive diabetes care. The market is segmented into monitoring and management devices. Within monitoring, self-monitoring blood glucose (SMBG) devices, including glucometers, test strips, and lancets, remain a substantial portion, although CGM is experiencing faster growth due to its real-time data capabilities and improved patient outcomes. The management device segment is dominated by insulin delivery systems like insulin pumps, syringes, pens, and jet injectors, with insulin pumps showing particularly strong growth prospects due to their convenience and efficacy in managing insulin delivery. Competitive intensity is high, with major players like Abbott, Medtronic, Dexcom, and Novo Nordisk vying for market share through continuous innovation and strategic partnerships. The North American region, particularly the US, holds a significant market share owing to high diabetes prevalence, advanced healthcare infrastructure, and strong regulatory support for innovative medical technologies. The market's growth trajectory is expected to remain positive through 2033, although certain restraints could influence the pace. These include high costs associated with some devices, particularly CGMs and insulin pumps, creating access barriers for some patients. However, increasing insurance coverage and the development of more affordable alternatives are mitigating these challenges. Furthermore, technological advancements, such as the integration of artificial intelligence and machine learning in diabetes management, are expected to further enhance the market's potential. Companies are focusing on developing integrated systems that combine CGM with insulin delivery, providing a more holistic approach to diabetes management. This trend will likely drive further growth and consolidation within the market. Future success will depend on companies' ability to innovate, offer competitive pricing strategies, and address the evolving needs of patients. Recent developments include: August 2023: The US Food and Drug Administration (FDA) has granted clearance for Roche's Accu-Chek Solo micropump system, a tubing-free "patch" pump for people with diabetes who use insulin., March 2022: Dexcom released G7 first in the U.K. and was expected to expand the launch across Europe throughout 2022. Meanwhile, the CGM system currently is under review by the Food and Drug Administration for an eventual U.S. release.. Key drivers for this market are: Increasing Number of Preterm and Low-weight Births, Advanced Technology in Fetal and Prenatal Monitoring. Potential restraints include: Stringent Regulatory Procedures. Notable trends are: Growing Diabetes and Obesity Population in the United States.

Snapshot img

Type 2 Diabetes Market Size 2025-2029

The type 2 diabetes market size is forecast to increase by USD 53.8 billion at a CAGR of 12.2% between 2024 and 2029.

The market is experiencing significant growth due to the rising prevalence of this chronic condition, particularly in the aging population. According to the International Diabetes Federation, approximately 463 million adults were living with diabetes in 2019, with this number projected to increase to 700 million by 2045. The geriatric population, which is disproportionately affected by Type 2 Diabetes, is expanding rapidly, with the number of people aged 65 and above expected to double by 2050. Despite this growing demand, there remains a low diagnosis rate for Type 2 Diabetes, presenting both an opportunity and a challenge for market participants. On the one hand, there is significant potential for companies to develop and market innovative diagnostic tools and treatments to improve early detection and management of the disease. On the other hand, the low diagnosis rate also highlights the need for increased public awareness and education campaigns to encourage individuals to seek testing and take preventative measures. In , the market is poised for growth due to demographic trends and the increasing prevalence of the disease. However, companies must navigate the challenge of low diagnosis rates by investing in innovative diagnostic solutions and public awareness campaigns to capitalize on this opportunity and meet the needs of this growing patient population.

What will be the Size of the Type 2 Diabetes Market during the forecast period?

Request Free SampleThe market in the US is experiencing significant growth due to the rising prevalence of the disease, particularly among young adults and adolescents. According to recent studies, an estimated 34.2 million Americans have diabetes, with Type 2 accounting for approximately 95% of cases. Factors contributing to market expansion include the increasing incidence of obesity, a known risk factor, and the aging population. Symptoms of Type 2 diabetes include increased thirst, frequent urination, blurred vision, fatigue, numbness or tingling in the hands or feet, slow-healing wounds, and neurological problems. The disease can also lead to complications such as heart disease, kidney damage, and nerve damage. Pharmaceutical companies are developing various therapeutic compounds to manage blood sugar levels, including insulin and non-insulin medications like Trulicity, Jardiance, and Tanzeum. These drugs are readily available at retail pharmacies and are essential for maintaining normal blood glucose levels and preventing complications. Additionally, the market is driven by the growing awareness of the importance of managing diabetes to prevent cardiovascular diseases and renal problems.

How is this Type 2 Diabetes Industry segmented?

The type 2 diabetes industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2025-2029, as well as historical data from 2019-2023 for the following segments. Drug ClassInsulinDPP-4 inhibitorGLP-1 receptor agonistsSGLT-2 inhibitorsOthersDistribution ChannelRetail pharmaciesHospital pharmaciesOnline pharmaciesDelivery ModeOralInjectableContinuous glucose monitoring (CGM)GeographyNorth AmericaUSCanadaEuropeFranceGermanyItalyUKAsiaChinaIndiaJapanSouth KoreaRest of World (ROW)

By Drug Class Insights

The insulin segment is estimated to witness significant growth during the forecast period.Type 2 diabetes mellitus is a chronic metabolic disorder characterized by insulin resistance and high blood glucose levels. Adolescents and young adults are among those frequently diagnosed with this condition, which can lead to complications such as numbness in hands and feet, blurred vision, and increased thirst and urination. The disease can also cause renal problems, including kidney damage and urine glucose excretion. Pharmaceutical companies are developing various therapeutic compounds to manage Type 2 diabetes. For instance, Sotagliflozin, a dual inhibitor of SGLT1 and SGLT2, is used to reduce blood glucose levels by increasing urine glucose excretion. Meglitinides, secretagogues that stimulate insulin secretion from the pancreas, are also used to improve glycemic control. Alpha-Glucosidase Inhibitors, such as Steglatro, delay the absorption of carbohydrates in the gut, thereby reducing blood glucose levels. Dipeptidyl Peptidase-4 Inhibitors, like Jardiance, help increase insulin secretion and decrease glucagon secretion, leading to improved blood sugar control. Insulin resistance is a significant factor in Type 2 diabetes, and medications like metformin, a Biguanide, help improve insulin sensitivity. Other oral medications, such as Sulfonylureas and Thiazolidinediones, also play a role in managing blood glucose levels. Maintain